Clinical Trials
21 trialsNCT07622342 2026-06-03
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2 Not yet recruiting
NCT07596784 2026-05-19
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Not yet recruiting
NCT07593911 2026-05-18
ArchAid-002
Beijing GoBroad Hospital
Phase NA Not yet recruiting
NCT07556120 2026-04-29
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT07499323 2026-04-08
Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
First Affiliated Hospital of Chongqing Medical University
Phase NA Not yet recruiting
NCT07463521 2026-03-17
MyVision
UCB Pharma
Phase 3 Not yet recruiting
NCT07465289 2026-03-11
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
UCB Pharma
Phase 3 Not yet recruiting
NCT07298928 2026-03-06
A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
The Children's Hospital of Zhejiang University School of Medicine
Phase NA Not yet recruiting
NCT07392528 2026-02-11
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07372807 2026-01-28
RIPERT-MG
Xinqiao Hospital of Chongqing
Phase 1/2 Not yet recruiting
NCT07323316 2026-01-07
HARMONY 360
Ad scientiam
Phase NA Not yet recruiting
NCT07243366 2025-11-21
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
Guangdong ProCapZoom Biosciences Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT07125105 2025-08-15
APART-MG
Universite du Littoral Cote d'Opale
Phase NA Not yet recruiting
NCT06978738 2025-05-18
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Changzhou No.2 People's Hospital
Phase 1 Not yet recruiting
NCT06933563 2025-04-18
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT06836973 2025-03-25
Blinatumomab for Treatment of Refractory Myasthenia Gravis
Da, Yuwei, M.D.
Phase 2/3 Not yet recruiting
NCT06827587 2025-02-14
Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis
First Affiliated Hospital of Wenzhou Medical University
Phase NA Not yet recruiting
NCT06759948 2025-01-06
KY2024-853
Huashan Hospital
Phase 1 Not yet recruiting
NCT06485232 2025-01-01
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1 Not yet recruiting
NCT06723548 2024-12-09
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
First Affiliated Hospital of Wenzhou Medical University
Phase 4 Not yet recruiting
NCT06221501 2024-01-24
Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting